Market Spotlight: Meningococcal Vaccines Disease
DISEASE OVERVIEW
Meningitis is an infection of the meninges, the membranes surrounding the brain and spinal
cord. It can be caused by a number of different viral and bacterial pathogens
including Haemophilus influenzae b (Hib) and Streptococcus pneumoniae. However, in the
US, Neisseria meningitidis is the most common cause of bacterial meningitis in infants and
young children, as well as one of the most important causes in adults. There are 13 known
serotypes of meningococcal disease, of which five (A, B, C, Y, and W-135) account for 90%
of the global disease burden.
MARKET SNAPSHOT
Continued uptake of MenB vaccines and GlaxoSmithKline's pentavalent vaccine launch from
2021 will drive market growth.
Cost-effectiveness concerns and scarcity of real-world effectiveness data are key resistors of
uptake for MenB vaccines.
Pipeline vaccines with broader serotype protection and novel approaches are positioned to
replace marketed products.
Exclusive Sample Report @
https://www.reportsworldwide.com/enquiry?report_id=42613
Major TOC Market:
FORECAST: MENINGOCOCCAL VACCINES (Published on 15 November 2017)
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
MARKET DEFINITION
US MARKET FORECAST
FRANCE MARKET FORECAST
GERMANY MARKET FORECAST
ITALY MARKET FORECAST
SPAIN MARKET FORECAST
UK MARKET FORECAST
KEY OPINION LEADER RESEARCH
MARKETED DRUGS: MENINGOCOCCAL VACCINES (Published on 15 November 2017)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: BEXSERO
PRODUCT PROFILE: MENACTRA
PRODUCT PROFILE: MENVEO
PRODUCT PROFILE: NIMENRIX
PRODUCT PROFILE: TRUMENBA
PIPELINE: MENINGOCOCCAL VACCINES (Published on 15 November 2017)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW